Andrew J. Bryant, MD

Andrew J. Bryant, MD
Clinical Assistant Professor

Email: andrew.bryant@medicine.ufl.edu

TEL: 352-273-8737


Degree/Program

Institution

Field/Specialty

MDWake Forest University School of Medicine 
ResidencyVanderbilt UniversityInternal Medicine
FellowshipVanderbilt UniversityPulmonary & Critical Care Medicine

Clinical Interests:

  • Pulmonary Hypertension
  • Interstitial Lung Disease

Research Interests:

Professional Societies:

  • American Thoracic Society
  • American College of Chest Physicians
  • Society for Critical Care Medicine
  • American College of Physicians

Honors and Awards:

  • 2006 – Alpha Omega Alpha
  • 2016 GIlead Sciences Research Scholars Program in Pulmonary Arterial Hypertension Award
  • 2017 Margaret Q. Landenberger Foundation Grant
  • American Lung Association Biomedical Research Grant
  • 2018 Parker B. Francis Fellowship Foundation Grant
  • 2019 Pulmonary Hypertension Accelerated Bayer (PHAB) Award
  • 2019 University of Florida Term Professorship Program – University Term Professor

Publications:

  • Bryant AJ, Shenoy V, Fu C, Marek G, Lorentsen KJ, Herzog EL, Brantly ML, Avram D, Scott EW.  Myeloid-derived suppressor cells are necessary for the development of pulmonary hypertension.  Am J Respir Cell Mol Biol. 2018 Feb;58(2):170-180.
  • Pi L, Fu C, Lu Y, Zhou J, Shenoy V, Lipson KE, Scott EW, Bryant AJ. Vascular endothelial cell-specific connective tissue growth factor (CTGF) is necessary for development of chronic hypoxia-induced pulmonary hypertension.  Front Physiol. 2018 Feb 27;9:138.
  • Rathinasabapathy A, Bryant AJ, Suzuki T, Moore C, Shay S, Gladson S, West JD, Carrier EJ. rhACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling. Front Physiol. 2018 Apr 9;9:271.
  • Bryant AJ, Mehrad B, Brusko TM, West JD, Moldawer LL.  Myeloid-derived suppressor cells and pulmonary hypertension.  Int J Mol Sci. 2018 Aug 3;19(8). pii: E2277.
  • Smith LC, Moreno S, Robertson L, Robinson S, Gant K, Bryant AJ, Sabo-Attwood T. Transforming growth factor beta1 targets estrogen receptor signaling in bronchial epithelial cells. Respir Res. 2018 Aug 30;19(1):160.
  • Bryant AJ, Fu C, Lu Y, Brantly ML, Mehrad B, Moldawer LL, Brusko TM, Brittain EL, West JD, Austin ED, Hamid R.  A checkpoint on innate myeloid cells in pulmonary arterial hypertension.  Pulm Circ. 2019 Jan-Mar;9(1):2045894018823528.
  • Oliviera AC, Fu C, Lu Y, Williams MA, Pi L, Brantly ML, Ventetuolo CE, Machuca TN, Raizada MK, Scott EW, Bryant AJ.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.  Am J Physiol Lung Cell Mol Physiol. 2019 Jul 31. doi: 10.1152/ajplung.00156.2019.